3-(pyridin-2-yl)quinoxalin-2(1H)-one | 7755-93-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(pyridin-2-yl)quinoxalin-2(1H)-one
• 英文别名: 3-(2)Pyridyl-chinoxalin-2-on；3-pyridin-2-yl-1H-quinoxalin-2-one；3-Pyridin-2-ylquinoxalin-2(1H)-one；3-pyridin-2-yl-1H-quinoxalin-2-one
• CAS: 7755-93-3
• 化学式: C₁₃H₉N₃O
• 分子量: 223.234
• InChiKey: NTNWESIGXKNYPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  三正丁基2-吡啶基锌 以 乙醇 、 苯 为溶剂， 反应 6.0h， 生成 3-(pyridin-2-yl)quinoxalin-2(1H)-one
  参考文献：
  名称：

  Powell, Paul; Sosabowski, Michael H., Journal of Chemical Research, Miniprint, 1995, # 10, p. 2422 - 2434

  摘要：

  DOI：

文献信息

• PHOTOREACTIVE REGULATOR OF GLUTAMATE RECEPTOR FUNCTION AND METHODS OF USE THEREOF
  申请人：Trauner Dirk

  公开号：US20090181454A1

  公开（公告）日：2009-07-16

  The present invention provides a synthetic regulator of glutamate receptor function, which regulator is a light-sensitive (photoreactive) regulator. The present invention further provides a light-regulated glutamate receptor that includes a subject synthetic regulator non-covalently associated with the glutamate receptor. Also provided are cells and membranes comprising a subject light-regulated glutamate receptor. The present invention further provides methods of modulating glutamate receptor function, involving use of light. The present invention further provides methods of identifying agents that modulate glutamate receptor function.

  本发明提供了一种合成的谷氨酸受体功能调节剂，该调节剂是一种光敏感（光反应性）调节剂。本发明还提供了一种光调节的谷氨酸受体，其中包括与谷氨酸受体非共价结合的主体合成调节剂。还提供了包括主体光调节谷氨酸受体的细胞和膜。本发明还提供了使用光调节谷氨酸受体的调节谷氨酸受体功能的方法。本发明还提供了识别调节谷氨酸受体功能的药剂的方法。
• Oxopyridinylquinoxaline derivatives
  申请人：SHIONOGI & CO., LTD.

  公开号：EP0676397A1

  公开（公告）日：1995-10-11

  An oxopyridinylquinoxaline derivative represented by the following Formula I or pharmaceutically acceptable salts thereof: wherein R¹ is hydrogen, halogen, nitro, or trihalomethyl; R² is hydrogen, halogen, nitro, cyano, trihalomethyl, carbamoyl, carbamoyl substituted with lower alkyl, sulfamoyl, or sulfamoyl substituted with lower alkyl; R³ is hydrogen, nitro, or halogen; R⁴ is hydrogen, lower alkyl, substituted lower alkyl, lower cycloalkyl, or substituted lower cycloalkyl; R5's are substituents independently selected from the group consisting of halogen, nitro, cyano, lower alkyl, carbamoyl, and carbamoyl substituted with lower alkyl; and n is an integer of 0 to 4. The derivative works as an antagonistic agent against both the NMDA receptors and the AMPA receptors, so that it is effective as a therapeutic agent for neurological disorders caused by excitatory amino acids binding to the receptors.

  下式 I 所代表的氧吡啶基喹喔啉衍生物或其药学上可接受的盐类： 其中R¹是氢、卤素、硝基或三卤甲基；R²是氢、卤素、硝基、氰基、三卤甲基、氨基甲酰基、被低级烷基取代的氨基甲酰基、氨基磺酰基或被低级烷基取代的氨基磺酰基；R³是氢、硝基或卤素；R⁴ 是氢、低级烷基、取代的低级烷基、低级环烷基或取代的低级环烷基；R5 是独立选自卤素、硝基、氰基、低级烷基、氨基甲酰基和被低级烷基取代的氨基甲酰基组成的取代基；以及 n 是 0 至 4 的整数。该衍生物对 NMDA 受体和 AMPA 受体均有拮抗作用，因此可有效治疗由兴奋性氨基酸与受体结合引起的神经紊乱。
• New use of glutamate antagonists for the treatment of cancer
  申请人：Ikonomidou, Hrissanthi

  公开号：EP1002535A1

  公开（公告）日：2000-05-24

  New therapies can be devised based upon a demonstration of the role of glutamate in the pathogenesis of cancer. Inhibitors of the interaction of glutamate with the AMPA, kainate, or NMDA receptor complexes are likely to be useful in treating cancer and can be formulated as pharmaceutical compositions. They can be identified by appropriate screens.

  根据谷氨酸在癌症发病机制中的作用，可以设计出新的疗法。谷氨酸与 AMPA、kainate 或 NMDA 受体复合物相互作用的抑制剂可能有助于治疗癌症，并可配制成药物组合物。它们可以通过适当的筛选来确定。
• Treatment of glial tumors with glutamate antagonists
  申请人：——

  公开号：US20030050224A1

  公开（公告）日：2003-03-13

  The present invention relates to a method of treating glial tumors in a subject, which includes providing a glutamate antagonist or a NMDA receptor antagonist and administering the glutamate antagonist or NMDA receptor antagonist to a subject with a glial tumor of the brain or spinal cord under conditions effective to treat the glial tumor.

  本发明涉及一种治疗受试者神经胶质瘤的方法，该方法包括提供谷氨酸拮抗剂或NMDA受体拮抗剂，并在有效治疗神经胶质瘤的条件下将谷氨酸拮抗剂或NMDA受体拮抗剂施用于患有脑或脊髓神经胶质瘤的受试者。
• Treatment of demyelinating disorders
  申请人：——

  公开号：US20040204347A1

  公开（公告）日：2004-10-14

  This invention is directed to pharmaceutical compositions and methods for treating demyelinating disorders based upon inhibitors of the interaction of glutamate with the AMPA and of the interaction of glutamate with the kainate receptor complex.

  本发明涉及治疗脱髓鞘疾病的药物组合物和方法，其基础是抑制谷氨酸与 AMPA 的相互作用以及谷氨酸与 kainate 受体复合物的相互作用的抑制剂。